has function has role immunizes against disease immunizes recipient melanoma Homo sapiens melanoma vaccine therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role MART-1/gp100/Tyrosinase/MAGE-A3 peptides-loaded irradiated allogeneic plasmacytoid dendritic cells vaccine Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses. cancer vaccine https://github.com/vaccineontology/VO/issues/504 Gene name: gp100 Gene name: MAGEA3 Jie Zheng 5028 Oliver He 6490 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5028 Yuanyi (Penny) Pan Justin Song 4100 therapeutic cancer vaccine